Search

Your search keyword '"Kaluzinski L"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Kaluzinski L" Remove constraint Author: "Kaluzinski L"
21 results on '"Kaluzinski L"'

Search Results

1. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

2. Efficacité en vraie vie de l’association nivolumab plus ipilimumab dans le mésothéliome pleural non résécable, naïf de traitement (étude GFPC MESO-IMMUNE)

3. Concordance entre la stratégie thérapeutique proposée en RCP initiale et le traitement effectivement réalisé pour les CBPNC de stade III non-résecables : résultats initiaux de l'étude OBSTINATE (GFPC 06-2019)

4. Concordance entre la stratégie thérapeutique proposée en RCP initiale et le traitement effectivement réalisé pour les CBPNC de stade III non opérables : résultats initiaux de l’étude OBSTINATE (GFPC 06-2019)

6. Qualité de vie (QdV) au diagnostic pour les patients porteurs d’un CBNPC de stade III non résécable : résultats de l’étude prospective nationale française OBSTINATE (GFPC 06-2019)

7. 148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial

8. Is There a Relationship Between Patient'S Satisfaction of the Diagnosis Announcement Device and Chemotherapy-Induced Nausea and Vomiting?

13. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

14. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

15. Supervised Physical Activity Quickly Improves Social Dimension of Quality of Life in Breast Cancer Patients.

16. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

18. [SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals].

19. How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.

20. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.

21. Evaluation of current practice: management of chemotherapy-related toxicities.

Catalog

Books, media, physical & digital resources